|
1
|
Naymagon L and Abdul-Hay M: Novel agents
in the treatment of multiple myeloma: A review about the future. J
Hematol Oncol. 9:522016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang Y, Sanchez L, Siegel DS and Wang ML:
Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol.
9:552016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gutman D, Morales AA and Boise LH:
Acquisition of a multidrug-resistant phenotype with a proteasome
inhibitor in multiple myeloma. Leukemia. 23:2181–2183. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee DM,
Kim KB and Lee W: Development of peptide-based reversing agents for
P-glycoprotein-mediated resistance to carfilzomib. Mol Pharm.
9:2197–2205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fuchs D, Berges C, Opelz G, Daniel V and
Naujokat C: Increased expression and altered subunit composition of
proteasomes induced by continuous proteasome inhibition establish
apoptosis resistance and hyperproliferation of Burkitt lymphoma
cells. J Cell Biochem. 103:270–283. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rückrich T, Kraus M, Gogel J, Beck A, Ovaa
H, Verdoes M, Overkleeft HS, Kalbacher H and Driessen C:
Characterization of the ubiquitin-proteasome system in
bortezomib-adapted cells. Leukemia. 23:1098–1105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bustany S, Cahu J, Descamps G,
Pellat-Deceunynck C and Sola B: Heat shock factor 1 is a potent
therapeutic target for enhancing the efficacy of treatments
formultiple myeloma with adverse prognosis. J Hematol Oncol.
8:402015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Richardson PG, Schlossman RL, Alsina M,
Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan
M, Paley CS, et al: PANORAMA 2: Panobinostat in combination with
bortezomib and dexamethasone in patients with relapsed and
bortezomib-refractory myeloma. Blood. 122:2331–2337. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Riz I, Hawley TS and Hawley RG:
KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to
carfilzomib resistance in multiple myeloma models. Oncotarget.
6:14814–14831. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu W, Chen Y, Xiang R, Xu W, Wang Y, Tong
J, Zhang N, Wu Y and Yan H: Novel phosphatidylinositol 3-kinase
inhibitor BKM120 enhances the sensitivity of multiple myeloma to
bortezomib and overcomes resistance. Leuk Lymphoma. 58:428–437.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hideshima T, Mitsiades C, Tonon G,
Richardson PG and Anderson KC: Understanding multiple myeloma
pathogenesis in the bone marrow to identify new therapeutic
targets. Nat Rev Cancer. 7:585–598. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bieghs L, Johnsen HE, Maes K, Menu E, Van
Valckenborgh E, Overgaard MT, Nyegaard M, Conover CA, Vanderkerken
K and De Bruyne E: The insulin-like growth factor system in
multiple myeloma: Diagnostic and therapeutic potential. Oncotarget.
7:48732–48752. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuhn DJ, Berkova Z, Jones RJ, Woessner R,
Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, et al:
Targeting the insulin-like growth factor-1 receptor to overcome
bortezomib resistance in preclinical models of multiple myeloma.
Blood. 120:3260–3270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jernberg-Wiklund H and Nilsson K: Control
of apoptosis in human multiple myeloma by insulin-like growth
factor I (IGF-I). Adv Cancer Res. 97:139–165. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hideshima T, Catley L, Yasui H, Ishitsuka
K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson
PG and Anderson KC: Perifosine, an oral bioactive novel
alkylphospholipid, inhibits Akt and induces in vitro and in vivo
cytotoxicity in human multiple myeloma cells. Blood. 107:4053–4062.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spencer A, Yoon SS, Harrison SJ, Morris
SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB and Chen
C: The novel AKT inhibitor afuresertib shows favorable safety,
pharmacokinetics, and clinical activity in multiple myeloma. Blood.
124:2190–2195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu L, Zhao N, Xu W, Sheng Z and Wang L:
Pooled analysis of the reports of carfilzomib, panobinostat, and
elotuzumab combinations inpatients with refractory/relapsed
multiple myeloma. J Hematol Oncol. 9:542016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu T, Li C, Wang L, Zhang Y, Peng L, Cheng
H, Chu Y, Wang W, Ema H, Gao Y, et al: PDK1 plays a vital role on
hematopoietic stem cell function. Sci Rep. 7:49432017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du J, Yang M, Chen S, Li D, Chang Z and
Dong Z: PDK1 promotes tumor growth and metastasis in a spontaneous
breast cancer model. Oncogene. 35:3314–3323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang C, Huang X, Liu H, Xiao F, Wei J, You
L and Qian W: PDK1 inhibitor GSK2334470 exerts antitumor activity
in multiple myeloma and forms a novel multitargeted combination
with dual mTORC1/C2 inhibitor PP242. Oncotarget. 8:39185–39197.
2017.PubMed/NCBI
|
|
21
|
Chinen Y, Kuroda J, Shimura Y, Nagoshi H,
Kiyota M, Yamamoto-Sugitani M, Mizutani S, Sakamoto N, Ri M, Kawata
E, et al: Phosphoinositide protein kinase PDPK1 is a crucial cell
signaling mediator in multiple myeloma. Cancer Res. 74:7418–7429.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Crawford LJ, Walker B, Ovaa H, Chauhan D,
Anderson KC, Morris TC and Irvine AE: Comparative selectivity and
specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and
MG-132. Cancer Res. 66:6379–6386. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He W, Ye X, Huang X, Lel W, You L, Wang L,
Chen X and Qian W: Hsp90 inhibitor, BIIB021, induces apoptosis and
autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and
-resistant chronic myeloid leukemia cells. Int J Oncol.
48:1710–1720. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Torres J and Pulido R: The tumor
suppressor PTEN is phosphorylated by the protein kinase CK2 at its
C terminus. Implications for PTEN stability to proteasome-mediated
degradation. J Biol Chem. 276:993–998. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Malek E and Driscoll JJ: High throughput
chemical library screening identifies a novel p110-δ inhibitor that
potentiates the anti-myeloma effect of bortezomib. Oncotarget.
7:38523–38538. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fujita T, Doihara H, Washio K, Kawasaki K,
Takabatake D, Takahashi H, Tsukuda K, Ogasawara Y and Shimizu N:
Proteasome inhibitor bortezomib increases PTEN expression and
enhances trastuzumab-induced growth inhibition in
trastuzumab-resistant cells. Anticancer Drugs. 17:455–462. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bononi A and Pinton P: Study of PTEN
subcellular localization. Methods. 77–78:92–103. 2015. View Article : Google Scholar
|
|
28
|
Gagliardi PA, Puliafito A and Primo L:
PDK1: At the crossroad of cancer signaling pathways. Semin Cancer
Biol. 48:27–35. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tu Y, Gardner A and Lichtenstein A: The
phosphatidylinositol 3-kinase/AKT kinase pathway in multiple
myeloma plasma cells: Roles in cytokine-dependent survival and
proliferative responses. Cancer Res. 60:6763–6770. 2000.PubMed/NCBI
|
|
30
|
Hsu J, Shi Y, Krajewski S, Renner S,
Fisher M, Reed JC, Franke TF and Lichtenstein A: The AKT kinase is
activated in multiple myeloma tumor cells. Blood. 98:2853–2855.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Keane NA, Glavey SV, Krawczyk J and
O'Dwyer M: AKT as a therapeutic target in multiple myeloma. Expert
Opin Ther Targets. 18:897–915. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Williams MR, Arthur JS, Balendran A, van
der Kaay J, Poli V, Cohen P and Alessi DR: The role of
3-phosphoinositide-dependent protein kinase 1 in activating AGC
kinases defined in embryonic stem cells. Curr Biol. 10:439–448.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Piras G, Monne M, Palmas AD, Calvisi A,
Asproni R, Vacca F, Pilo L, Gabbas A and Latte G: Methylation
analysis of the phosphates and tensin homologue on chromosome 10
gene (PTEN) in multiple myeloma. Clin Epigenetics. 6:162014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Naidu S, Magee P and Garofalo M:
MiRNA-based therapeutic intervention of cancer. J Hematol Oncol.
8:682015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Di Martino MT, Gullà A, Cantafio ME,
Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F,
Cannataro M, et al: In vitro and in vivo anti-tumor activity of
miR-221/222 inhibitors in multiple myeloma. Oncotarget. 4:242–255.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang X, Chen Y, Zhao P, Zang L, Zhang Z
and Wang X: MicroRNA-19a functions as an oncogene by regulating
PTEN/AKT/pAKT pathway in myeloma. Leuk Lymphoma. 58:932–940. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang SY, Hao HL, Deng K, Li Y, Cheng ZY,
Lv C, Liu ZM, Yang J and Pan L: Expression levels of phosphatase
and tensin homolog deleted on chromosome 10 (PTEN) and focal
adhesion kinase in patients with multiple myeloma and their
relationship to clinical stage and extramedullary infiltration.
Leuk Lymphoma. 53:1162–1168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fragoso R and Barata JT: Kinases, tails
and more: Regulation of PTEN function by phosphorylation. Methods.
77–78:75–81. 2015. View Article : Google Scholar
|
|
40
|
Ho J, Bassi C and Stambolic V:
Characterization of nuclear PTEN and its post translational
modifications. Methods. 77–78:104–111. 2015. View Article : Google Scholar
|
|
41
|
Chang CJ, Mulholland DJ, Valamehr B,
Mosessian S, Sellers WR and Wu H: PTEN nuclear localization is
regulated by oxidative stress and mediates p53-dependent tumor
suppression. Mol Cell Biol. 28:3281–3289. 2008. View Article : Google Scholar : PubMed/NCBI
|
